

Supplemental Figure 1: Consort diagram of study population

2,140 eligible men from AGES-Reykjavik
Eligibility criteria included: 1) answers to questions about sleep, 2) recorded time of urine sample delivery, 3) gave informed consent for use of hospital data, 4) were not part of the home visit group

**Subcohort selection:
randomly selected 50% sample**

1,070 chosen for subcohort

1,070 not chosen for subcohort

15 inadequate urine samples
191 prevalent cancer

Additional exclusions post subcohort selection

5 inadequate urine samples
245 prevalent cancer

Final subcohort: 864

Final non-subcohort: 820

Case identification


Incident prostate cancer cases: 47

Non-cases: 817

Incident prostate cancer cases: 64

Total incident prostate cancer cases: 111

Supplemental Figure 2: Association between mean 6-sulfatoxymelatonin levels and sleep disruption in the subcohort, AGES-Reykjavik case-cohort study



Adjusted for age and creatinine

*Statistically significant difference at $p < 0.05$; **Statistically significant difference at $p < 0.10$